Background: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and cancer
immunotherapy targeting the immune checkpoint PD-1 will soon become the standard of
care (SoC) in the treatment of HCC [1]. Nevertheless, not all patients benefit equally
from this therapy. In order to better understand the difference between responders
and non-responders, we established two orthotopic HCC mouse models with distinct morphological,
angiogenic, genetic and immunological characteristics and investigated the therapeutic
response to frequently used immune checkpoint blockers (ICBs) in comparison to the
current SoC sorafenib.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
P01. Preclinical models P01.01
Identification
Copyright
© 2018 Published by Elsevier Inc.
